Biogen | Actif À Court Terme



Current Assets Changement Date
AbbVie USD 25.58B 2.2B 2024-12
Acadia Pharmaceuticals USD 938.32M 150.03M 2024-12
ALKERMES USD 1.42B 167.74M 2024-12
Amgen USD 29.03B 2.26B 2024-12
Bayer EUR 34.44B 1.31B 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Eli Lilly USD 32.74B 1.32B 2024-12
Gilead Sciences USD 19.17B 4.39B 2024-12
Incyte USD 3.24B 430.32M 2024-12
Intra Cellular Therapies USD 1.31B 35.63M 2024-12
Merck USD 38.78B 1.58B 2024-12
Moderna USD 8.1B 1.57B 2024-12
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 50.36B 7.14B 2024-12
PTC Therapeutics USD 1.37B 83.98M 2024-12
Regeneron Pharmaceuticals USD 27.21B 7.88B 2024-12
Sanofi 30.08B 589M 2024-06
Sanofi 30.08B 589M 2024-06
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
Teva Pharmaceutical Industries USD 12.55B 238M 2024-12
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
United Therapeutics USD 3.87B 126.5M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Biogen Actif À Court Terme - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.